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Background. Chronic renal failure (CRF) is associated with
increased plasma levels of ghrelin and leptin, but the regulation
of the secretion of these hormones has been insufficiently stud-
ied, in this setting. The aim of this study was to analyze the acute
effects of oral feeding or intraperitoneal 3.86% glucose-based
dialysate infusion on plasma ghrelin and leptin levels in patients
with CRF undergoing peritoneal dialysis (PD).
Methods. Following a crossover design, 10 patients and eight
healthy controls underwent a standardized oral intake, a 3.86%
glucose-based dialysate PD exchange (patients) and placebo
oral intake. We scrutinized acute changes in plasma ghrelin,
leptin, glucose, insulin, and growth hormone (GH) levels.
Results. In patients, total ghrelin decreased modestly imme-
diately after oral feeding (nadir 90.6% of baseline, range 85.1,
94.5, P =0.03) or the PD exchange test (92.2%, range 58.7, 101.9,
P = 0.05) (median). Response to oral feeding was markedly
blunted when compared with healthy individuals (73.8%, range
56.1, 89.1, P = 0.007) (P < 0.005 vs. patients). Plasma acyl-
ghrelin had a less marked but more persistent decay after the
PD exchange test (nadir 80.4%, range 55.1, 96.3, P = 0.02) than
after oral intake (64.4%, range 45.6, 82.3, P = 0.005); again,
changes were more intense in normal controls (47.4%, range
32.1, 67.3, P = 0.01) (P < 0.05 vs. patients). Leptin levels de-
creased slightly (P < 0.05) after the PD exchange in patients, but
did not respond acutely to oral feeding in patients or controls.
Conclusion. Ghrelin secretion is partially refractory to the
acute inhibitory effect of oral feeding in patients with CRF un-
dergoing PD therapy. A 3.86% glucose-based PD exchange re-
sults in a significant decrease of plasma ghrelin levels. Plasma
leptin levels are not acutely affected by oral feeding in patients
with CRF or healthy individuals.
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The mechanisms that regulate appetite, energy bal-
ance, and body weight in health and disease are very
complex and remain only partially understood, despite
extensive investigation in this field in the last several
decades [1–4]. The majority of the hormones and other
humoral factors known to participate in these processes
appear to originate in the adipose tissue or the gastroin-
testinal tract, and have their main targets in the lower
brain [3–6]. Among them, leptin, a satiety factor secreted
mainly by adipocytes [7, 8], and ghrelin, an orexigenic
hormone produced for the most part by specialized cells
in the stomach [9–11], have emerged as two significant
short- and long-term regulators of appetite and body
weight, besides participating in a wide spectrum of other
endocrine and nonendocrine processes, to an extent we
are only beginning to disclose [3, 12].
The physiologic regulations of leptin and ghrelin are
apparently disordered in patients with chronic renal fail-
ure (CRF). Both plasma leptin [13–25] and ghrelin [26–
28] levels have been repeatedly found to be increased in
patients with CRF, treated or not with dialysis. However,
the meaning of these abnormalities is still unclear, for dif-
ferent reasons. First, the physiologic significance of these
two hormones has not yet been fully clarified in healthy
individuals, which hinders interpretation of apparent dis-
orders observed in patients with CRF. On the other hand,
studies on leptin and ghrelin in patients with CRF have
generally been limited to cross-sectional or longitudinal
screening of their fasting plasma levels, providing a lim-
ited view of the problem. Moreover, the interpretation
of the results of some of these studies may be controver-
sial. For instance, the majority of the studies on ghrelin
in the CRF setting published so far have focused on total
ghrelin, despite the fact that supposedly active, acylated
ghrelin does not represent the same fraction of total ghre-
lin in normal individuals and in patients with CRF [26].
On the other hand, there is a notable lack of information
on how the secretion of these two hormones is regulated
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in patients with CRF, as compared with normal individu-
als. Patients treated with chronic peritoneal dialysis (PD)
may represent a particularly interesting setting to ana-
lyze this question because periodic intraperitoneal instil-
lation of glucose-based dialysate may further impair the
regulation of these hormones by different mechanisms,
including semi-continuous glucose absorption, hyperin-
sulinism, or increased adiposity. Leptin [20, 24, 25, 29],
but not ghrelin [27], plasma levels have been reported to
be higher in patients treated with PD than in those un-
dergoing hemodialysis. Analysis of these issues may help
to understand the pathogenesis of anorexia and malnu-
trition in patients with CRF.
We have performed a crossover study to disclose
the acute effects of a standardized oral feeding or
the intraperitoneal infusion of hypertonic glucose-based
dialysate on plasma levels of ghrelin and leptin in a group
of nondiabetic patients undergoing chronic PD therapy.
METHODS
General design
Following a crossover design, 10 nondiabetic patients
undergoing chronic PD therapy and eight healthy con-
trols, matched for age, sex, and body mass index, were
scrutinized for acute ghrelin and leptin responses to
a standardized oral feeding, hypertonic glucose-based
dialysate, and orally administered placebo. Thus, every
patient underwent three tests, and every control two tests
(oral feeding and placebo), with a time span of 40 days
for the whole sample retrieval period. Tests were carried
out in a randomized order. The study protocol fulfilled
the requirements of the ethical committee of our center,
and written informed consent was obtained from both
patients and controls.
Subjects
Patients were randomly selected from our population
undergoing chronic continuous ambulatory peritoneal
dialysis (CAPD) therapy, after applying the follow-
ing exclusion criteria: diabetes mellitus, age <30 or
>70 years, significant clinical events during the previ-
ous three months, and unwillingness or inability to co-
operate. Controls were selected from a pool of healthy
volunteers available to the Endocrinology Unit of our
center. The main characteristics of both groups are pre-
sented in Table 1. One patient and one control were obese
(body mass index >30 kg/m2). No patient reported overt
anorexia or suffered a significant clinical event during the
study period. The results of a standard peritoneal equili-
bration test (PET), carried out a median of 3 months be-
fore the study (range 1–6), were available for all patients.
Table 1. Study population
Patients Controls P
Age years 56 (36–65) 53 (36–61) 0.36
Gender male/female 5/5 4/4 1.00
Body mass index kg/m2 24.7 (20.7–32.0) 25.7 (20.1–31.3) 0.63
Time on dialysis months 11 (3–63) – –
D/P240’ creatininea 0.62 (0.47–0.80) – –
Figures denote median values (range) (numerical variables) and number of
cases (gender). Comparisons by Mann-Whitney U test and Fisher exact test.
a Standard 2.27% peritoneal equilibration test.
Protocol
Patients were instructed to perform a single nightime
PD exchange using either 1.36% glucose or icodextrin-
based dialysate (Baxter, Deerfield, IL, USA) the day
before the test. After an overnight fast, all tests started
between 8:30 AM and 9:00 AM. Patients and controls were
put at rest in a sitting position, and a peripheral venous
line was obtained. Thirty minutes later, both received, in
three different days: (1) a standardized oral feeding con-
sisting of 400 mL of Isosource Energy (Novartis, Zurich,
Switzerland), containing 5.7 g of protein, 6.2 g of lipid, and
20 g of carbohydrate per 100 mL, for a total caloric con-
tent of 158.8 kcal/100 mL (14.4% protein, 35.1% lipid,
50.4% carbohydrate). The first PD exchange of the day
was delayed until the end of the test, in patients. (2) A
PD exchange, consisting of 2 liters of dialysate (Baxter)
with a glucose concentration of 3.86 g/dL (patients). Peri-
toneal fluid was drained at the end of the test (120 min-
utes after infusion) to calculate total peritoneal glucose
absorption, and patients were kept fasting until the end
of the test. (3) Orally administered placebo (400 mL of
tap water). Patients/controls were kept fasting and, again,
the first PD exchange of the day was delayed until the end
of the test, in patients.
We obtained blood samples for ghelin, leptin, insulin,
glucose, and growth hormone (GH) at baseline and then
at times 30, 45, 60, and 120 minutes. Plasma cortisol levels
were estimated at baseline of each test. Baseline samples
of the oral feeding test were used to estimate plasma lev-
els of interleukin-6 and high-sensitivity C-reactive pro-
tein (hsCRP).
Sample management and laboratory methods
All blood samples were immediately centrifuged,
separated, and frozen at −80◦C. Samples destined to
determination of plasma ghrelin levels were specifi-
cally retrieved to chilled tubes containing aprotinin and
EDTA-Na, and then immediately centrifuged at 4◦C, sep-
arated to aliquots, and frozen at −80◦C.
For estimation of the scrutinized hormones we used
the following specific commercial methods: total ghrelin
(RIA; Phoenix Pharmaceuticals, Belmont, CA, USA),
acylated ghrelin (RIA; Linco, St. Charles, MO, USA),
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leptin (RIA; Mediagnost, Tu¨bingen, Germany), in-
sulin (RIA; CIS Bio International, Cedex, France), GH
(RIA; Nichols Inst. Diagnostics, San Juan Capistrano,
CA, USA), and cortisol (Chemoluminiscence; ADVIA
Centaur System, Bayer, Leverkusen, Germany). Plasma
interleukin-6 levels were estimated by enzyme-linked im-
munosorbent assay (ELISA; R&D Systems, Minneapolis,
MN, USA), and hsCRP levels, using an immuno-
turbidimetric method (Roche Diagnostics, Mannheim,
Germany). Plasma and dialysate glucose levels were es-
timated using a standard autoanalyzer.
Secondary calculations
The time courses of plasma ghrelin and leptin levels
after the different tests were analyzed in absolute terms
and also as% change versus baseline, the latter to over-
come potential biases induced by significantly different
baseline plasma levels of both hormones in patients and
controls. Glucose absorption during the hypertonic PD
exchange test was estimated by simple mass balance.
Resistance to insulin was estimated indirectly accord-
ing to the Homeostasis Model Assessment (HOMA)
score [plasma insulin (lUI/mL) × plasma glucose
(mmol/L)/22.5] [30].
Statistics
All comparisons were based on univariate, nonpara-
metric tests. Intragroup comparisons (changes versus
baseline and oral vs. intraperitoneal vs. placebo) were
based on Wilcoxon’s test. Comparisons between patients
and controls were based on Fisher (categorical) and
Mann-Whitney U (numerical) tests. Numerical correla-
tions were analyzed using the Spearman’s correlation
test. P values ≤ 0.05 were considered to be significant.
For graphic representation we used mean values ± SEM.
The SPSS software 12.0 (Chicago, IL, USA) was used to
produce statistical analysis.
RESULTS
Overview
Baseline levels of the different hormones scrutinized
are presented in Table 2. Both plasma total ghrelin
and leptin levels tended to be higher in patients than
in healthy individuals. On the contrary, plasma acyl-
ghrelin levels were not significantly different between
both groups. Plasma acyl-ghrelin levels represented a me-
dian of 11.4% of simultaneous total ghrelin levels (range
2.3–23.9) in patients (30 estimations), as compared with
19.4% (range 7.7–29.8) in controls (16 estimations) (P =
0.001). Moreover, we observed a better correlation be-
tween total and acylated ghrelin levels in controls (r =
0.56, P = 0.03) than in patients (r = 0.31, P = 0.11).
Both plasma total and acylated ghrelin levels showed a
trend to an inverse correlation with age in patients (r =
Table 2. Baseline plasma hormone levels
Patients Controls P
Total ghrelin pg/mL
Oral feeding test 960 (728–1302) 731 (399–1016) 0.06
Oral placebo test 933 (784–1252) 669 (411–1023) 0.02
Hypertonic glucose-based
dialysate test
1022 (696–1238) —
Acylated ghrelin pg/mL
Oral feeding test 97 (35–185) 140 (43–193) 0.07
Oral placebo test 106 (19–188) 112 (39–227) 0.97
Hypertonic glucose-based
dialysate test
128 (28–211) —
Leptin ng/mL
Oral test 41.4 (3.6–170.8) 9.3 (3.0–24.1) 0.04
Placebo test 36.0 (0.7–103.6) 11.1 (2.7–30.5) 0.08
Hypertonic glucose-based
dialysate test
36.2 (3.3–94.9) —
Insulin lUI/mL
Oral test 14.5 (5.1–25.3) 9.5 (3.7–16.1) 0.04
Placebo test 13.1 (6.9–20.4) 9.7 (2.8–15.0) 0.09
Hypertonic glucose-based
dialysate test
13.5 (6.7–22.5)
HOMA score
Oral test 3.03 (1.70, 7.81) 2.26 (0.75, 4.05) 0.12
Placebo test 3.02 (1.89, 4.55) 2.61 (0.57, 3.83) 0.24
Hypertonic glucose-based
dialysate test
2.52 (1.58, 5.71) —
Plasma growth hormone ng/mL
Oral 3.52 (0.18, 9.50) 0.72 (0.01, 2.20) 0.08
Placebo 2.51 (0.19, 5.80) 1.35 (0.01, 6.53) 0.17
Hypertonic glucose-based
dialysate test
2.19 (0.16, 5.30) —
Plasma cortisol lg/dL
Oral 14.1 (5.0, 21.9) 12.3 (10.0, 16.2) 0.51
Placebo 16.3 (7.1, 20.0) 13.3 (9.4, 18.8) 0.41
Hypertonic glucose-based
dialysate test
14.4 (5.4, 22.9) —
Figures denote median values (range) at baseline of each test. Comparisons
by Mann-Whitney U test. Intragroup differences not significant.
−0.52, P = 0.09, and r = −0.51, P = 0.10, respectively)
and controls (r = −0.76, P = 0.03, and r = −0.69, P =
0.06, respectively).
Plasma interleukin-6 levels were significantly higher
in patients (median 7.4 pg/mL, range 0.0, 32.9) than in
healthy controls (median 0.0 pg/mL, range 0.0, 8.0) (P =
0.006). A similar, but less marked trend was observed for
hsCRP, with median levels of 2.1 mg/L (range 0.2, 13.8)
for patients versus 0.7 mg/L (range 0.2, 1.4) for controls
(P =0.08). We observed no trend to a correlation between
these inflammatory markers and baseline plasma ghrelin
or leptin levels, either in patients or controls.
Total ghrelin
The time courses of plasma total ghrelin levels in
patients and controls are displayed in Figure 1A and
B, respectively. In patients, oral intake and the hyper-
tonic glucose-based PD exchange resulted in compara-
ble, modest, but significant decreases of plasma ghrelin
levels, with nadir values of 90.6% (median, range 85.1,
94.5, P = 0.03) (oral) and 92.2% (range 58.7, 101.9, P =
0.05) (PD exchange) versus baseline. However, response
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Fig. 1. Plasma total ghrelin levels after oral feeding, placebo and
3.86% glucose-based dialysate infusion in patients (A) and controls
(B). Figures denote% change versus baseline (mean ± SEM). Compar-
isons by Wilcoxon’s (intragroup) and Mann-Whitney U tests (patients
vs. controls). Oral feeding patients versus controls P < 0.001 except
120 minutes (P = 0.02). PD exchange (patients) versus oral feeding
(controls). P < 0.005 except 120 minutes (P = 0.034).
to oral feeding appeared markedly blunted when com-
pared with healthy controls, who reached nadir values
of 73.8% (range 56.1, 89.1, P = 0.007) versus baseline
(P < 0.005 patients vs. controls). When changes in plasma
ghrelin levels were analyzed in absolute terms, maximum
falls versus baseline observed were 88 pg/mL (median)
(range 56, 170) (oral) and 79.5 pg/mL (range −17, 324)
(PD exchange) in patients (oral vs. PD exchange not sig-
nificant NS), as compared with 202 pg/mL (range 45, 428)
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Fig. 2. Plasma acylated ghrelin levels after oral feeding, placebo, and
3.86% glucose-based dialysate infusion in patients (A) and controls (B).
Figures denote% change versus baseline (mean ± SEM). Comparisons
by Wilcoxon’s (intragroup) and Mann-Whitney U tests (patients vs. con-
trols). Oral feeding patients versus controls P < 0.05 except 45 minutes
(P = 0.11). PD exchange (patients) versus oral feeding (controls). P <
0.05 any point after baseline.
in healthy controls (P < 0.05 vs. patients, either oral or
PD exchange) (median values). These differences were
already apparent at 30 minutes, with median falls of 22
(oral) and 55 pg/mL (PD exchange) in patients versus
113 pg/mL in controls (P < 0.002).
Acylated ghrelin
Changes in acyl-ghrelin levels are depicted in Figure 2A
(patients) and B (controls). Again, oral intake and the test
PD exchange resulted in significant decreases of ghre-
lin levels in patients. In this case the response was less
marked, although more persistent after the PD exchange
(median nadir 80.4% vs. baseline, range 55.1, 96.3, P =
0.02) than after oral intake (nadir 64.4%, range 45.6, 82.3,
P = 0.005 vs. baseline) (P < 0.05 oral vs. PD exchange).
On the other hand, changes in acylated ghrelin levels af-
ter oral intake were less marked and sustained in patients
than in healthy controls, the latter reaching median
nadir values of 47.4% (range 32.1, 67.3) versus baseline
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Fig. 3. Plasma leptin levels after oral feeding, placebo, and 3.86%
glucose-based dialysate infusion in patients (A) and controls (B). Fig-
ures express % change versus baseline (mean ± SEM). Comparisons by
Wilcoxon’s (intragroup) and Mann-Whitney U tests (between patients
and controls). Differences between patients and controls not significant.
(P = 0.01) (P < 0.05 patients vs. controls). When changes
in plasma acyl-ghrelin levels were analyzed in absolute
terms, maximum falls versus baseline were 36 pg/mL
(range 12, 113) (oral) and 48 pg/mL (range 8, 92) (PD
exchange) in patients (oral vs. PD exchange NS), as com-
pared with 102 pg/mL (range 26, 129) in controls (oral)
(P < 0.05 vs. patients, either oral or PD exchange) (me-
dian values). Similar to the case of total ghrelin, differ-
ences were already significant at 30 minutes, with falls
of 14 (oral) and 30 pg/mL (PD exchange) in patients, as
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Fig. 4. Plasma glucose levels after oral feeding, placebo, and 3.86%
glucose-based dialysate infusion in patients (A) and controls (B)
(mean ± SEM). Comparisons by Wilcoxon’s (intragroup) and Mann-
Whitney U tests (patients vs. controls). Differences between patients
and controls not significant.
compared with 79 pg/mL in controls (P < 0.05) (median
values).
Leptin
Changes in plasma leptin levels during the study tests
are presented in Figure 3A (patients) and B (controls).
Leptinemia decreased slightly, but significantly after the
hypertonic glucose-based PD exchange (P <0.05 vs. base-
line). On the contrary, neither in patients nor controls did
oral feeding or placebo modify plasma leptin levels.
Glucose, insulin, and GH
In patients, median glucose absorption 120 minutes af-
ter the hypertonic glucose PD exchange was 36.9 g (range
29.3–56.8). Figures 4 and 5 display glucose and insulin
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Fig. 5. Plasma insulin levels after oral feeding, placebo, and 3.86%
glucose-based dialysate infusion in patients (A) and controls (B) (mean
± SEM). Comparisons by Wilcoxon’s (intragroup) and Mann-Whitney
U tests (patients vs. controls). Baseline levels P = 0.04 (oral), patients
versus controls. Other differences between patients and controls not
significant.
responses to the applied stimuli in patients and con-
trols. Peripheral insulinemia increased more markedly
after oral feeding than after the PD exchange in pa-
tients, despite a slightly higher glycemic peak in the latter
experiment.
We did not detect a correlation between baseline
plasma total or acylated ghrelin levels or changes after
oral intake or the hypertonic PD exchange on one side,
and baseline or peak levels of glucose or insulin dur-
ing these tests, on the other. In healthy individuals, the
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Fig. 6. Plasma growth hormone levels after oral feeding, placebo, and
3.86% glucose-based dialysate infusion in patients (A) and controls (B)
(mean ± SEM). Comparisons by Wilcoxon’s (intragroup) and Mann-
Whitney U tests (patients vs. controls). Differences between patients
and controls not significant.
HOMA score showed a significant inverse correlation
with baseline plasma total (r = −0.60, P = 0.09) and acy-
lated ghrelin (r = −0.76, P = 0.03) levels, and showed
a similar, but nonsignificant trend to correlate with nadir
values for acyl-ghrelin after the oral feeding test. No such
correlations were observed in patients.
Figure 6 depicts changes in GH levels during the differ-
ent tests. In general, a tendency to a modest decrease in
plasma GH was the rule in all the experiments (including
placebo), without intra- or intergroup differences, or ap-
parent correlations with changes in plasma ghrelin levels.
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DISCUSSION
Several cross-sectional and longitudinal studies have
demonstrated that plasma leptin [13–25] and ghrelin [26–
28] levels are significantly increased in patients with CRF
when compared to normal individuals. Some of these
studies have also scrutinized potential correlations be-
tween plasma levels of these two regulators of appetite,
and selected demographic, clinical, and biochemical pa-
rameters, trying to disclose a role of these hormones as
links between malnutrition, inflammation, and cardiovas-
cular disease in these patients. In general, attempts to
demonstrate a role for leptin or ghrelin in the pathogen-
esis of anorexia and malnutrition of CRF using this ap-
proach have yielded unconcluding results. Importantly,
obesity (in many patients a positive surrogate of feeding
habits and of the global nutritional status) is normally as-
sociated with high leptin [7] and low ghrelin [12] plasma
levels, and this correlation appears to be essentially pre-
served in uremic patients [15, 25, 27, 28]. This reverse epi-
demiology setting [31] may hamper attempts to uncover a
negative effect of abnormal leptin or ghrelin levels on the
regulation of the feeding drive and the nutritional status
of patients with CRF [28, 32]. Despite this strong method-
ologic limitation, some groups have been able to detect
subtle correlations between leptinemia [19, 21, 28, 29, 33]
or ghrelinemia [34] and the nutritional state of patients
with CRF. On the other hand, leptin is being progres-
sively recognized as a proinflammatory cytokine with a
significant part in the pathogenesis of the metabolic syn-
drome [35], but its role as a link between inflammation
and malnutrition in patients with CRF is not yet clear
[22, 29, 36]. The effect of inflammation on plasma ghrelin
levels has been less studied, but both in the present study
and in a previous report [27], we were unable to disclose
a correlation between plasma levels of this hormone and
selected proinflammatory cytokines. Overall, the existent
studies have not provided answers to some relevant ques-
tions, including how the secretion of these two hormones
is acutely regulated in patients with CRF, what are the
relative roles of distorted secretory patterns and abnor-
mal disposal in the genesis of high blood levels, or what
are the consequences of the observed abnormalities in
these patients.
The physiologic significance of different fractions of
circulating ghrelin is a current subject of interest. It is
generally assumed that acylation by n-octanoic acid of
the hydroxyl group of serine in position 3 of the molecule
of ghrelin is essential for the physiologic activity of this
hormone [9], and this appears to be true for the main
endocrine functions of this hormone [12]. However, de-
sacylated ghrelin, which represents 80% to 90% of circu-
lating ghrelin in normal individuals [37], may still retain
some significant, not yet well defined functions [3, 12]. In
fact, desacyl-ghrelin has been claimed to oppose or mod-
ulate some of the physiologic effects of acyl-ghrelin [38,
39]. It is even conceivable that high circulating desacyl-
ghrelin levels may paradoxically reduce the feeding drive
by a competitive mechanism with acylated ghrelin. These
considerations can be particularly relevant in patients
with CRF in whom desacyl-ghrelin levels are markedly
increased, while acyl-ghrelin levels are not significantly
different from those observed in normal individuals, as
shown by our own results (Table 2), in agreement with
previous reports [26].
In normal individuals, plasma ghrelin levels reach a
maximum immediately before, and decrease acutely af-
ter a meal [40, 41], supporting the notion that ghrelin has
a pivotal role in the acute regulation of appetite and oral
intake. These events are at least partially mediated by
changes in plasma glucose and/or insulin levels [12]. In
our patients, total ghrelin levels decreased significantly
immediately after oral feeding, but this variation was
markedly blunted when compared with healthy controls
(Fig. 1). It may be argued that a higher proportion of
retained desacyl-ghrelin fragments could mask a normal
physiologic response, but analysis of absolute changes in
total ghrelin levels during the test supported the existence
of an attenuated response in patients. Most importantly,
changes in plasma acyl-ghrelin levels (Fig. 2) provided
definite evidence of a less marked, but still significantly
blunted inhibition of ghrelin secretion by oral feeding in
CRF.
The mechanisms underlying the partial loss of the phys-
iologic response of ghrelin secretion to oral intake in pa-
tients with CRF are not clear. Refractoriness of plasma
ghrelin secretion to feeding has also been reported in
children [42] and patients with obesity [43] or anorexia
nervosa [44]. In the latter setting, persistently high plasma
ghrelin levels have been considered to represent an adap-
tive response to a chronically low intake [44]. However,
this mechanism cannot be invoked in our case because
baseline acyl-ghrelin levels were not different in patients
and controls. On the other hand, some of the physio-
logic mechanisms modulating ghrelin secretion may be
altered by CRF. For instance, the glycemic and insuline-
mic profiles of our patients after the oral feeding test were
not patently abnormal (Figs. 4 and 5), but persistent hy-
perinsulinism and relative resistance to insulin may still
have distorted their ghrelin secretion patterns. Finally, we
must consider the possibility that high concentrations of
desacyl-ghrelin in patients with CRF may interfere with
the normal secretory mechanisms of ghrelin.
Our results do not support a significant role for ghre-
lin in the pathogenesis of anorexia of patients with CRF.
In fact, the partial refractoriness of ghrelin secretion to
the inhibitory effect of oral intake should, at first sight,
increase rather than reduce the feeding drive of these
patients. However, the central response to ghrelin af-
ter the partial abolition of the normal secretory cycles
of this hormone could be modulated by compensatory
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mechanisms, including changes in the secretory patterns
of other regulators of appetite and competitive inhibition
of the effect of acyl-ghrelin by persistently high plasma
levels of desacyl-ghrelin, as previously commented. High-
dose, exogenously administered ghrelin is able to increase
appetite in malnourished PD patients [45]. Further stud-
ies are clearly needed to clarify these questions.
In our study, changes in plasma total ghrelin levels were
very similar after oral feeding and 3.86% glucose-based
dialysate instillation in patients (Fig. 1A). On the con-
trary, the response of acyl-ghrelin levels to hypertonic
dialysate was less marked, although more persistent than
the response to oral feeding (Fig. 2A). However, direct
comparison between both experiments is not possible, for
at least three reasons. First, the carbohydrate load to our
patients was similar, or even higher, after oral intake than
after the infusion of 3.86% glucose-based dialysate, and
oral feeding included also a lipid and a protein load. In
addition, glucose absorption is probably slower, but more
persistent after a hypertonic glucose-based PD exchange
than after an oral intake, providing a direct explanation
for the different time profiles of acyl-ghrelin levels in both
tests (Fig. 2A). Finally, we have to consider the possibil-
ity that peritoneal clearance of ghrelin during the PD
exchange test may have influenced the differences ob-
served. In general, carbohydrate loads appear to inhibit
ghrelin secretion more efficiently than lipid or protein
loads in healthy individuals [45], matching the notion that
the acute fall in plasma ghrelin levels after oral feeding
is basically secondary to changes in glycemia [41, 47, 48]
and/or insulinemia [49–51]. On the other hand, studies
after gastric bypass surgery have demonstrated that the
ghrelin secretory response may be down-regulated if the
contact of the nutrients with the stomach is suppressed
[52, 53], indicating a local effect of food on gastric ghrelin
secretion. As a whole, our study demonstrates that hyper-
tonic glucose-based dialysate is able to reduce modestly,
but significantly, plasma levels of total and acylated ghre-
lin. This finding may contribute to explain the inhibitory
effect of hypertonic glucose-based PD fluids on the feed-
ing drive of patients undergoing PD therapy.
Serum leptin levels are generally considered as a rather
static marker of total fat mass [54], although they may
respond moderately to short-term fasting and refeeding
[55]. Leptinemia has been sporadically claimed to in-
crease acutely after oral feeding in lean [43] and obese
individuals [56]. Contrary to the latter reports, we did
not disclose any acute effect of oral intake on plasma lep-
tin levels, either in patients or controls (Fig. 3). In fact,
we observed a generalized, modest trend to a decrease in
plasma leptin levels during the tests, reaching statistical
significance only after hypertonic glucose-based dialysate
infusion in patients. The latter finding may be secondary
to a combination of peritoneal clearance of leptin dur-
ing the PD exchange test [24, 57, 58] and/or of circadian
changes in leptinemia [59]. Intraperitoneal glucose has
been demonstrated to exert a direct stimulatory effect of
leptin secretion by adipocytes, but this effect may not be
apparent before 24 to 48 hours after stimulation [60].
CONCLUSION
Plasma total ghrelin levels decreased modestly, and
plasma acyl-ghrelin more markedly, after a standardized
oral feeding in patients with chronic renal failure treated
with PD. However, these changes were significantly at-
tenuated when compared with those observed in healthy
controls, indicating that ghrelin secretion is partially re-
fractory to the acute inhibitory effect of oral intake in
these patients. A hypertonic glucose-based dialysate PD
exchange was able to reduce significantly plasma levels
of total and acylated ghrelin. Plasma leptin levels are not
acutely affected by feeding, either in patients with chronic
renal failure or healthy controls.
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